Defining the Role for Topically Administered Tranexamic Acid in Panniculectomy Surgery.
Abstract
[BACKGROUND] Abdominal panniculectomy after weight loss is a commonly performed procedure with high patient satisfaction yet continues to have a high post-operative complication profile. Several risk-reducing surgical approaches, such as preservation of Scarpa's fascia, use of tissue adhesives, and progressive tension suture techniques have been described. However, the use of tranexamic acid (TXA) has not been previously reported in panniculectomy surgery.
[OBJECTIVES] To improve the safety and predictability of this procedure, the authors investigate whether the use of topically administered TXA during panniculectomy surgery reduces seroma, hematoma, and drain duration.
[METHODS] Consecutive patients who underwent panniculectomy (January 2010 to January 2022) were retrospectively reviewed. Outcome measures included hematoma requiring surgical evacuation, seroma requiring percutaneous aspiration, and drain duration. Patients with thromboembolic diseases and those taking anticoagulation/antiplatelet medications were excluded. Patients who had received TXA were compared with a historical control group who had not received TXA.
[RESULTS] A total of 288 consecutive patients were included. Topical TXA was administered in 56 (19.4%) cases. The mean (standard deviation [SD]) follow-up was 43.9 (37.4) months (3.7 years). The median (range) resection weight was 2.6 kg (0.15-19.96 kg). Regarding seroma and hematoma formation, the use of TXA did not reduce the likelihood of developing seroma or hematoma (odds ratio [OR] = 1.7, 95% CI [0.56- 4.8], = 0.38 and OR = 2.1, 95% CI [0.4-11.8], = 0.42), respectively. The mean (SD) duration of drains was slightly lower in the TXA group (18.1 [12.1] days vs 19.8 [13.9] days); however, this difference was not statistically significant, albeit clinically significant.
[CONCLUSIONS] As the use of TXA in plastic surgical procedures continues to expand, the utility of TXA in panniculectomy and abdominoplasty has not been elucidated. Although previous studies report hematoma and seroma risk reduction, the use of TXA was not associated with a statistically significant reduction in seroma, hematoma, or drain duration following panniculectomy surgery. Prospective, randomized controlled studies on the use of TXA in body contouring are needed.
[OBJECTIVES] To improve the safety and predictability of this procedure, the authors investigate whether the use of topically administered TXA during panniculectomy surgery reduces seroma, hematoma, and drain duration.
[METHODS] Consecutive patients who underwent panniculectomy (January 2010 to January 2022) were retrospectively reviewed. Outcome measures included hematoma requiring surgical evacuation, seroma requiring percutaneous aspiration, and drain duration. Patients with thromboembolic diseases and those taking anticoagulation/antiplatelet medications were excluded. Patients who had received TXA were compared with a historical control group who had not received TXA.
[RESULTS] A total of 288 consecutive patients were included. Topical TXA was administered in 56 (19.4%) cases. The mean (standard deviation [SD]) follow-up was 43.9 (37.4) months (3.7 years). The median (range) resection weight was 2.6 kg (0.15-19.96 kg). Regarding seroma and hematoma formation, the use of TXA did not reduce the likelihood of developing seroma or hematoma (odds ratio [OR] = 1.7, 95% CI [0.56- 4.8], = 0.38 and OR = 2.1, 95% CI [0.4-11.8], = 0.42), respectively. The mean (SD) duration of drains was slightly lower in the TXA group (18.1 [12.1] days vs 19.8 [13.9] days); however, this difference was not statistically significant, albeit clinically significant.
[CONCLUSIONS] As the use of TXA in plastic surgical procedures continues to expand, the utility of TXA in panniculectomy and abdominoplasty has not been elucidated. Although previous studies report hematoma and seroma risk reduction, the use of TXA was not associated with a statistically significant reduction in seroma, hematoma, or drain duration following panniculectomy surgery. Prospective, randomized controlled studies on the use of TXA in body contouring are needed.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | txa
|
트라넥삼산 | dict | 11 | |
| 시술 | panniculectomy
|
복부성형술 | dict | 7 | |
| 합병증 | hematoma
|
혈종 | dict | 6 | |
| 합병증 | seroma
|
장액종 | dict | 6 | |
| 약물 | tranexamic acid
|
트라넥삼산 | dict | 2 | |
| 시술 | abdominoplasty
|
복부성형술 | dict | 1 | |
| 해부 | tissue
|
scispacy | 1 | ||
| 약물 | Administered Tranexamic Acid
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Abdominal panniculectomy
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | anticoagulation/antiplatelet
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 약물 | CI [
|
scispacy | 1 | ||
| 약물 | drains
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | weight loss
|
C1262477
Weight Loss
|
scispacy | 1 | |
| 질환 | thromboembolic
|
C0333214
thromboembolic
|
scispacy | 1 | |
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | Scarpa
|
scispacy | 1 | ||
| 기타 | fascia
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Case report of a rare soft tissue tuberculosis in a patient undergoing lipoabdominoplasty.
- What is the potential role of the nonopioid suzetrigine in pain management?
- Otoplasty for prominent ear: A systematic review of surgical techniques.
- Combined minimally invasive lymphatic microsurgery and aligned nanofibrillar collagen scaffold for refractory post-traumatic eyelid lymphedema: A case report.
- Tranexamic Acid in Reconstructive Microsurgery: A Systematic Review and Meta-Analysis.